Live Breaking News & Updates on Grosshansdorf

Stay informed with the latest breaking news from Grosshansdorf on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Grosshansdorf and stay connected to the pulse of your community

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Geneva , Genè , Switzerland , Germany , Manchester , United-kingdom , Grosshansdorf , Schleswig-holstein , Henrik-watz , Dennis-riedl , Dave-singh , Maria-bech

EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

REYKJAVIK, Iceland, April 10, 2024--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

United-kingdom , Grosshansdorf , Schleswig-holstein , Germany , Reykjavik , C10- , Iceland , Geneva , Genè , Switzerland , Manchester , Ginny-norris

Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation

Switzerland - Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced that the European Commission granted conditional marketing authorization for KRAZATI as a...

Switzerland , Liechtenstein , Norway , Germany , Grosshansdorf , Schleswig-holstein , Iceland , Martin-reck , Charles-baum , European-commission , Exchange-commission , European-union

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that the European Commission granted...

Switzerland , Liechtenstein , Iceland , Norway , Germany , Grosshansdorf , Schleswig-holstein , Charles-baum , Martin-reck , Nasdaq , Union-register , Committee-for-medicinal-products-human-use

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Grosshansdorf , Schleswig-holstein , Germany , Iceland , Norway , Liechtenstein , Martin-reck , Charles-baum , Committee-for-medicinal-products-human-use , European-commission , Nasdaq , Mirati-therapeutics-inc

Adagrasib Approved in Europe for Pretreated KRAS G12C+ Advanced NSCLC

The European Commission has granted conditional marketing authorization to adagrasib for use in adult patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation whose disease progressed following at least 1 prior systemic treatment.

Iceland , Germany , Singapore , Liechtenstein , Grosshansdorf , Schleswig-holstein , Norway , Martin-reck , Adagrasib-krazati , European-commission , Mirati-therapeutics-inc , European-union

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Liechtenstein , Norway , Iceland , Germany , Grosshansdorf , Schleswig-holstein , Charles-baum , Martin-reck , Mirati-therapeutics-inc , Prnewswire-mirati-therapeutics-inc , European-medicines-agency

CHMP Recommends Adagrasib for Pretreated KRAS G12C+ Advanced NSCLC

After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.

Germany , Grosshansdorf , Schleswig-holstein , Alan-sandler , Martin-reck , Adagrasib-krazati , European-commission , European-union , Mirati-therapeutics-inc , European-medicines-agency , Medicinal-products , Human-use

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that following a re-examination...

United-kingdom , Grosshansdorf , Schleswig-holstein , Germany , Switzerland , Martin-reck , Alan-sandler , Nasdaq , Twitter , Committee-for-medicinal-products-human-use , Healthcare-products-regulatory-agency , Exchange-commission

Mirati Therapeutics (MRTX) Receives Positive Opinion from CHMP for KRAZATI

Mirati Therapeutics (MRTX) Receives Positive Opinion from CHMP for KRAZATI
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , Grosshansdorf , Schleswig-holstein , Martin-reck , Alan-sandler , Nasdaq , Mirati-therapeutics-inc , European-union , Committee-for-medicinal-products-human-use , European-medicine-agency , European-commission , Mirati-therapeutics